Inside Rossari Biotech earnings: Input cost falls twice as much as revenue

Advertisement
Inside Rossari Biotech earnings: Input cost falls twice as much as revenue
Rossari
Advertisement
The Mumbai-based speciality chemical maker Rossari Biotech just went through a super hot IPO, and an even better listing. However, its first quarterly earnings as a listed entity was much less exciting.

Rossari recorded 14.3% fall in revenue to ₹109.4 crore but its net profit grew 7.4% to ₹15.2 crore as the cost of goods consumed in the making of its products fell by nearly a third. The input cost was the biggest saving in the latest earnings report.

Rossari BiotechStandalone earnings
Profit 7.4%
Revenue-14.30%

Rossari makes popular household products like Vim, Rin, Ciff and Surf for the brand owners like Hindustan Unilever, Dabur, IFB, Arvind, Raymond, and many more to name a few. “In-home care, personal care and performance, we have 3 verticals. In one vertical, we make the ingredients, and these ingredients go into soap, detergents, paper, pulp, ceramic and tiles. They may constitute between 2-10% of the total product,” Rossari Biotech executive chairman and co-founder, Edward Menezes told Business Insider in a pre-listing conversation.

Inside Rossari Biotech earnings: Input cost falls twice as much as revenue

It was a bumper listing for Rossari, the shares made its debut on July 23, listing almost 57% higher on BSE against the issue price of ₹425. The IPO was held from July 13 to July 15 and was the first of its kind after COVID impacted the Indian stock-market.

Advertisement

Since then, shares have been riding on positive sentiments. It has gained nearly 8% since its listing and ended over 4% higher ahead of the earnings today.

Inside Rossari Biotech earnings: Input cost falls twice as much as revenue

The company was also a top mid and small-cap buy of mutual funds in July. According to reports, the mutual funds also bought the newly listed speciality chemical stock Rossari Biotech worth ₹407 crore.

SEE ALSO: Here’s a look at the top IPOs lined up to hit the market this year
Rossari Biotech IPO⁠— 40 scientists, China, and other factors that make the share sale hot
{{}}